Verdence Capital Advisors LLC Sells 1,098 Shares of AstraZeneca PLC (NASDAQ:AZN)

Verdence Capital Advisors LLC decreased its stake in AstraZeneca PLC (NASDAQ:AZNFree Report) by 6.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 16,472 shares of the company’s stock after selling 1,098 shares during the quarter. Verdence Capital Advisors LLC’s holdings in AstraZeneca were worth $1,109,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Fairfield Bush & CO. bought a new position in shares of AstraZeneca in the 2nd quarter valued at about $25,000. ICA Group Wealth Management LLC bought a new position in shares of AstraZeneca in the 4th quarter valued at about $26,000. Anchor Investment Management LLC bought a new position in shares of AstraZeneca in the 4th quarter valued at about $26,000. Parkside Financial Bank & Trust grew its holdings in shares of AstraZeneca by 4,875.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after acquiring an additional 390 shares in the last quarter. Finally, Compagnie Lombard Odier SCmA bought a new position in AstraZeneca during the fourth quarter worth about $27,000. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. Jefferies Financial Group cut AstraZeneca from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Finally, Morgan Stanley initiated coverage on AstraZeneca in a report on Tuesday, January 23rd. They set an “overweight” rating for the company. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $80.00.

View Our Latest Stock Report on AZN

AstraZeneca Trading Up 0.3 %

Shares of NASDAQ:AZN opened at $68.55 on Monday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $76.56. The stock has a market cap of $212.54 billion, a PE ratio of 35.70, a P/E/G ratio of 1.26 and a beta of 0.50. The business has a 50 day moving average of $66.24 and a 200-day moving average of $65.87. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.57.

AstraZeneca (NASDAQ:AZNGet Free Report) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.73 earnings per share for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). AstraZeneca had a net margin of 13.00% and a return on equity of 30.19%. The business had revenue of $12.02 billion during the quarter, compared to analyst estimates of $12.07 billion. During the same quarter in the previous year, the firm posted $0.69 earnings per share. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. As a group, equities research analysts forecast that AstraZeneca PLC will post 4 earnings per share for the current year.

AstraZeneca Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Monday, March 25th. Stockholders of record on Friday, February 23rd were given a $0.965 dividend. This represents a dividend yield of 2.3%. This is an increase from AstraZeneca’s previous Semi-Annual dividend of $0.47. The ex-dividend date of this dividend was Thursday, February 22nd. AstraZeneca’s payout ratio is presently 100.52%.

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Articles

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.